The phosphatase and tensin homologue deleted on chromosome 10 mediates radiosensitivity in head and neck cancer by Pattje, W J et al.
The phosphatase and tensin homologue deleted on chromosome
10 mediates radiosensitivity in head and neck cancer
WJ Pattje
1,2, E Schuuring
2, MF Mastik
2, L Slagter-Menkema
1,2,3, ML Schrijvers
2,3, S Alessi
4,
BFAM van der Laan
3, JLN Roodenburg
5, JA Langendijk
1 and JE van der Wal*,2
1Department of Radiation Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands;
2Department of
Pathology and Medical Biology (HPC EA10), University Medical Center Groningen, University of Groningen, PO Box 30.001, Groningen 9700 RB,
The Netherlands;
3Department of Otorhinolaryngology and Head and Neck Surgery, University Medical Center Groningen, University of Groningen,
Groningen, The Netherlands;
4Sapienza–Universita ` di Roma, Rome, Italy;
5Department of Oral and Maxillofacial Surgery, University Medical Center
Groningen, University of Groningen, Groningen, The Netherlands
                  
BACKGROUND: For locally advanced squamous cell carcinoma of the head and neck (HNSCC), the recurrence rate after surgery and
postoperative radiotherapy is between 20 and 40%, and the 5-year overall survival rate is B50%. Presently, no markers exist to
accurately predict treatment outcome. Expression of proteins in the human epidermal growth factor receptor (EGFR) pathway has
been reported as a prognostic marker in several types of cancer.
METHODS: The aim of this study was to investigate the prognostic value of proteins in the EGFR pathway in HNSCC. For this purpose,
we collected surgically resected tissue of 140 locally advanced head and neck cancer patients, all treated with surgery and
postoperative radiotherapy.
RESULTS: In a multivariate analysis, expression of the phosphatase and tensin homologue deleted on chromosome 10 (PTEN) was
significantly related to worse locoregional control (LRC; HR: 2.2, 95% CI: 1.1–4.6; P¼0.03), independent of lymph node metastases
(HR: 5.6, 95% CI: 1.2–27.4; P¼0.03) and extranodal spread (HR: 2.7; 95% CI: 1.2–6.5; P¼0.02). In vitro clonogenic radiosensitivity
assays confirmed that overexpression of PTEN resulted in increased radioresistance.
CONCLUSION: Our study is the first report showing that expression of PTEN mediates radiosensitivity in vitro and that increased
expression in advanced HNSCC predicts worse LRC.
British Journal of Cancer (2010) 102, 1778–1785. doi:10.1038/sj.bjc.6605707 www.bjcancer.com
Published online 25 May 2010
& 2010 Cancer Research UK
Keywords: PTEN; HNSCC; radiosensitivity; locoregional control; EGFR pathway
The prognosis for patients with locally advanced head and neck
squamous cell carcinoma (HNSCC) depends on numerous clinical
and histopathological factors. Despite intensive curative treatment
strategies, such as surgery and postoperative radiotherapy,
20–40% of all patients will develop a locoregional recurrence
(LRR) and the 5-year overall survival rate remains B50%
(Le Tourneau et al, 2008). For this reason, attempts have been
made to identify molecular markers that are able to improve the
identification of tumours that will develop LRR and thus might
benefit from more aggressive treatment strategies (Partridge et al,
2005). One of the potential prognostic factors is the epidermal
growth factor receptor (EGFR), which has been identified as
an important prognostic marker in several other cancer types
(Mellon et al, 1995; Fischer-Colbrie et al, 1997; Inada et al, 1999;
Kersemaekers et al, 1999; Galizia et al, 2006). The human
epidermal growth factor receptor (HER) family of tyrosine kinase
receptors consists of four family members, of which the EGFR
(EGFR/HER1/erbB1) and HER2 (HER2/NEU/erbB2) are the best
known members (Rogers et al, 2005). Binding of the ligands for
EGFR, such as TGF-a and EGF, to the extracellular domain of
the receptor triggers a dimerisation of the receptors, resulting
in autophosphorylation of the tyrosine-rich intracellular domain
of EGFR. On activation, the receptors can either homodimerise
or heterodimerise with other HER family members, such as HER2.
This activated form of the receptor initiates two major downstream
signalling pathways, the PI3K/AKT pathway and the Ras/Raf/
MEK/ERK pathway. Activation of these pathways leads to
increased proliferation, desensitisation to apoptosis and increased
angiogenesis (Yarden and Sliwkowski, 2001; McKay and Morrison,
2007; Jiang and Liu, 2008).
A number of studies reported that overexpression of the EGFR
protein (Grandis et al, 1998; Ang et al, 2002; Pivot et al, 2005) is
associated with worse prognosis in HNSCC. However, in other
studies, the association between the levels of EGFR expression and
clinical outcome could not be confirmed (Eriksen et al, 2004; Smid
et al, 2006; Fischer et al, 2008). There are various explanations for
the differences between these studies, such as various antibodies,
protocols and scoring methods. In addition, it has been shown that
amplification of the EGFR gene is predictive for clinical outcome in
HNSCC (Chung et al, 2006). As EGFR amplification analysis by
fluorescent in situ hybridisation (FISH) is more reproducible than
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smost immunohistochemical (IHC) staining procedures, this might
prove to be a more valuable tool for prognosis than IHC.
The aim of this study was to investigate the prognostic value
of EGFR, HER2 and their downstream pathway targets with regard
to locoregional control (LRC) in locally advanced HNSCC. For
this purpose, tumour specimens of HNSCC patients treated
with surgery and postoperative radiotherapy were collected.
In addition, we performed in vitro clonogenic survival assays to
confirm the hypothesis that followed from the results of the clinical
part of our study.
MATERIAL AND METHODS
Patients and tissues
This study cohort was composed of consecutive patients diagnosed
with HNSCC, uniformly treated with primary surgery and
postoperative radiotherapy at the University Medical Center
Groningen, The Netherlands, between 1993 and 2003. Clinical
and histopathological data of all these patients were collected
(n¼198) with a follow-up of at least 3 years. Formalin-fixed
paraffin-embedded surgically resected tissue of the primary
tumour was collected and revised by an experienced pathologist
(JEvdW). In 167 cases, sufficient tumour material was available to
construct a tissue microarray (TMA). In this study, we included
140 patients for whom IHC stainings for all antigens were
assessable. The pre-treatment characteristics of these patients are
summarised in Table 1. In summary, the study cohort mainly
consisted of male patients, with a median age of 60 years (range
24–90), with predominantly more advanced T-stage (T3–T4 in
74%), lymph node metastasis (64%) and advanced-stage (84%
stage III and IV) cancers.
All patients underwent surgery of the primary tumour followed
by postoperative radiotherapy. In 128 of the cases (91%), a neck
dissection was performed. Postoperative radiotherapy was admi-
nistered because of positive surgical margins (69%), lymph node
metastases with extranodal spread (36%) and/or other adverse
prognostic factors such as advanced T-stage, multiple lymph node
metastases and/or perineural growth. Local recurrence was defined
as a recurrence within 2cm of the original tumour site and
occurring within a 3-year period. Tumours arising more than
3 years after therapy were considered as second primary tumours.
TMA construction
To construct TMAs, 5-mm-thick sections were cut from paraffin-
embedded formalin-fixed tissue blocks, slides were prepared and a
standard haematoxylin and eosin (H and E) staining was
performed. The representative regions in the tumour were marked
on the H and E-stained slides by an experienced pathologist. Three
cores of 0.6mm diameter were taken from each donor block and
put into the recipient paraffin block using the Manual Tissue
Arrayer 1 (Beecher Instruments, Silver Spring, MD, USA). Six
different normal tissue controls and one oropharyngeal SCC were
included on each TMA block to ensure similarity of staining
between the slides, orientation on the TMA and recognition of
each TMA. Our series of 167 carcinomas was distributed on four
TMAs. Sections (5mm thick) from each TMA block were cut and
the first section was stained with H and E to confirm the presence
of tumour cells in each core. Using TMAs with three cores with a
diameter of 0.6mm is considered to be representative for the
heterogeneousness of the tumour (Camp et al, 2000; Kallioniemi
et al, 2001).
IHC staining
Tissue microarray sections were deparaffinised in xylene and
rehydrated. Antigen retrieval was performed by heating in a
microwave oven for 15min in 10mM citrate buffer (pH¼6.0; for
pERK, pAKT, PTEN); in EDTA (pH¼8.0; for pEGFR); in a pressure
cooker, three times for 5min at 1151C (for PI3K); for 30min at
951C in a Tris buffer (pH¼9.5; for EGFR); or for 30min at 951C
in cell conditioner 1 buffer (Roche Diagnostics/Ventana, Basel,
Switzerland) (for HER2).
After antigen retrieval, the endogenous peroxidase was blocked
with a 0.3% peroxide solution. The following primary antibodies
were used: EGFR (clone EGFR113, Novocastra (Newcastle upon Tyne,
UK), ready to use), pEGFR (clone 1H12, Cell Signalling (Danvers, MA,
USA), 1:200), PTEN (clone 6H2.1, Cascade (Winchester, MA, USA),
1:100), PI3K p110 (sc-1331, Santa Cruz Biotechnology, Santa Cruz,
CA, USA, 1:50), pAKT (ser473) (clone 736E11, Cell Signalling, 1:50),
pERK (clone 20G11, Cell Signalling, 1:50) and HER2 (clone CB11,
Roche Diagnostics/Ventana, ready to use).
For immunodetection, we used appropriate biotinylated (PTEN,
pEGFR, pERK) or horseradish peroxidase (HRP)-conjugated
(PI3K) secondary antibody or Envision (Dako, Glostrup,
Denmark) (pAKT) followed by appropriate HRP-conjugated
tertiary antibody (PI3K) or HRP-conjugated streptavidin (PTEN,
pEGFR, pERK) and developed with 3,30-di-aminobenzidine
chromogen solution (Dako) followed by a routine haematoxylin
counterstaining.
Table 1 Patient characteristics
Characteristic N (%)
Total 140 (100)
Age
Median (range), years 60 (24–90)
Gender
Female 46 (33)
Male 94 (67)
Primary location
Larynx 28 (20)
Hypopharynx 8 (6)
Oropharynx 25 (18)
Oral cavity 79 (56)
T status
T1 6 (4)
T2 30 (22)
T3 34 (24)
T4 70 (50)
N status
N0 50 (36)
N+ 90 (64)
N1 32 (23)
N2a 1 (1)
N2b 42 (30)
N2c 13 (9)
N3 2 (1)
Stage
I 1 (1)
II 21 (15)
III 17 (12)
IV 101 (72)
Resection margins
Free 43 (31)
Not free 97 (69)
Extra nodal spread
Yes 51 (36)
No 89 (64)
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Staining intensity was semi-quantitatively scored as negative (0),
weak positive (þ), positive (þþ) and strong positive (þþþ)
staining. For statistical analysis, any positive staining above
background was considered as positive. In addition, the percentage
of positive cells was recorded. In case of differences between cores,
scores were averaged for statistical analyses.
For the EGFR and HER2 staining, no and incomplete mem-
branous staining were considered negative, and only complete
IHC staining of tumour cell membranes above the background
was considered positive, independent of the intensity and
percentage of positive cells according to the standard Herceptest
protocol.
The cases were considered positive for the pEGFR staining if
20% or more of the cells had membranous, cytoplasmic or nuclear
staining; positive for pAKT if 27.5% or more of the tumour cells
had cytoplasmic staining; positive for PTEN when 7.5% or more of
the tumour cells showed a cytoplasmic staining; and positive for
PI3K when more than 35% of the tumour cells had cytoplasmic
staining. The cutoff percentages are based on receiver operating
characteristic curve analyses for LRR (data not shown) (Zweig and
Campbell, 1993). The cases were considered positive for pERK
if there was nuclear staining in any of the tumour cells.
Evaluation of immunostaining was performed independently by
two observers without information on the clinical data. In case
of discrepancies between the observers, cases were reviewed
with an experienced pathologist and scored on consensus opinion.
Only patients with at least two representative cores were included
in the analysis.
Fluorescent in situ hybridisation
Fluorescent in situ hybridisation analysis was used to determine
copy number changes of the EGFR gene. Tissue microarray
sections were deparaffinised in xylene and rehydrated, pre-treated
in a pressure cooker at 1201C in a Tris/EDTA (pH 9.0) buffer,
incubated with RNAse A and with 0.1% pepsin and dehydrated in
an ethanol gradient. The DNA was denatured for 12min at 801C
with the dual-colour EGFR/CEP7 FISH probes (Vysis LSI EGFR
SpectrumOrange/CEP 7 SpectrumGreen probe from Abbott,
Hoofddorp, The Netherlands) and hybridised at 371C overnight.
The sections were incubated in a 0.3% NP-40 solution at 731C
and a 0.1% NP-40 solution at RT. The sections were dehydrated
and covered by a drop of DAPI (1:3000) in Vectashield (Vector
Laboratories, Burlingame, CA, USA) and covered by a coverslip.
Images were captured using a Leica DMRA2 fluorescence
microscope (Leica Microsystems, Wetzlar, Germany) equipped
with a Leica DC 350F charge-coupled device camera. Digital
images were processed with Leica CW4000 software. Interphase
nuclei were examined by eye and the orange and green signals
were counted separately in B20 nuclei per core. The ratio between
EGFR (orange) and centromere 7 signals provides an accurate
estimation of copy number differences. A ratio of 1.0 indicates
normal copy (or polyploidy of chromosome 7 if 43 signals of both
probes are observed per nucleus), a ratio o1 is loss and 42i s
gain. Nuclei were considered to contain amplification of EGFR
when the number of signals exceeded five (and ratio 42.5).
Statistical analysis
Statistical analysis was carried out using the SPSS 14.0.0 software
package (SPSS Inc., Chicago, IL, USA). Association between different
markers and between markers and clinicopathological characteristics
were performed using the w
2-test. The primary end point used in this
study was LRC, which was defined by the time from surgery until the
first LRR in the case of an event or from the time from surgery until
the last follow-up date in the case of no event.
For the univariate and multivariate analysis of clinical outcome,
a Cox regression analysis was used. The categorised covariates that
showed a trend (Po0.10) in the univariate analysis were put into
a back-step multivariate Cox regression analysis. P-values o0.05
were considered significant. Kaplan–Meier survival curves for
LRC were created to illustrate the differences.
Cell culture and transfection
The Hek293 cell line was cultured in DMEM (1gl
 1 glucose)
with 10% fetal bovine serum, 2mM ultra-glutamine, penicillin
and streptomycin (all purchased from BioWhittaker, Basel,
Switzerland). The cells were transfected using Fugene 6 reagent
(Roche Allied Sciences, Almere, The Netherlands), as described
by the manufacturer, with the empty vector pcDNA3 or the
pcDNA3–GFP–PTEN (Addgene plasmid 10759). From one day
after transfection on, the cells were cultured in DMEM containing
800mgml
 1 Geneticin (Invitrogen, Carlsbad, CA, USA). Geneticin-
resistant colonies were separately cultured, and the expression
of GFP/PTEN was confirmed using FACS analysis for GFP and
immunostaining on western blot using an antibody for PTEN
(clone 28H6, 1:500; Santa Cruz Biotechnology).
Clonogenic survival assay to determine radiation response
in vitro
The 96-well plate clonogenic assay based on limiting dilutions
was used as described previously in detail (Grenman et al, 1989).
The data are based on the average of three independent
experiments.
RESULTS
To assess the expression levels of proteins and phosphoprotein
isoforms having an active role in the EGFR pathway in locally
advanced HNSCC, IHC was performed on TMAs containing
primary tumour material from patients with HNSCC who were
all treated with primary surgery and postoperative radiotherapy.
In 140 HNSCCs, EGFR was positive in 17 cases (12%), pEGFR in
56 cases (40%), PI3K in 53 cases (38%), PTEN in 43 cases (31%),
pAKT in 35 cases (25%), pERK in 22 cases (16%) and HER2 in
11 cases (8%) (See examples in Supplementary Figure 1).
PTEN expression is associated with EGFR activation
To determine whether the activation of the EGFR pathway
resulted in the simultaneous activation of other downstream
EGFR pathway targets, we performed cross-table analysis between
all targets (Table 2). A significant association was found between
the expression of EGFR and its activated isoform (pEGFR)
(P¼0.027) (Table 2a). In addition, pEGFR staining and pERK
staining were found to be associated (P¼0.001) (Table 2b).
The pERK staining showed an inverse relationship with the
PI3K staining (P¼0.004) (Table 2c) and a positive correlation with
PTEN-positive staining (P¼0.028) (Table 2d). Positive staining
for PI3K was associated with positive staining for HER2
(P¼0.028) (Table 2e). Surprisingly, a positive pAKT staining
showed a positive association with PTEN positivity (Po0.001)
(Table 2f). Combinations of other stainings were not associated
significantly (Supplementary Table 1).
EGFR expression is associated with more advanced-stage
tumours
The correlations between IHC staining and clinicopathological
characteristics showed that tumours with a high percentage
of pAKT-positive cells had an increased risk on lymph node
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EGFR correlated with lower T-stages (T1–T2) (w
2¼4.6; P¼0.032)
and with lower stages (stage I–III) (w
2¼9.2; P¼0.002). For
the other clinicopathological characteristics, no associations were
found with any of the IHC stainings (Supplementary Table 1).
EGFR expression is strongly associated with DNA
amplification
We found high-copy DNA amplification of the EGFR gene in
14 out of the 118 assessable cases (12%). Immunohistochemical
EGFR protein expression was significantly associated with DNA
amplification (w
2¼85.22; Po0.0001) as 13 of 16 positive cases
showed amplification in contrast to only 1 of 102 EGFR-negative
cases. The IHC staining for EGFR was shown to be highly
specific (97%) and highly sensitive (93%) for EGFR amplification
(Table 3). Interestingly, the only case with EGFR amplification
that was scored IHC negative (because of lack of membranous
staining) showed the strongest cytoplasmic staining among the
other cases.
PTEN predicts LRC
To investigate whether expression of EGFR and its downstream
targets were associated with clinical outcome, we performed
univariate Cox regression analysis. Expression of PTEN (HR: 2.4;
95% CI: 1.2–5.0) and pAKT (HR: 2.2; 95% CI: 1.0–4.6) were
significantly associated with a worse LRC (Table 4). Locoregional
control was also significantly worse in case of lymph node
metastases (HR: 5.7; 95% CI: 2.0–16.3) and in case of extranodal
spread (HR: 5.0; 95% CI: 2.4–10.6). The multivariate Cox
regression analysis for LRC showed that PTEN (HR: 2.2; 95% CI:
1.1–4.6), extranodal spread (HR: 2.7; 95% CI: 1.2–6.5) and the
presence of lymph node metastasis (HR: 5.7; 95% CI: 1.2–27.4)
were all independent prognostic factors for LRC. Kaplan–Meier
survival analysis showed that patients with PTEN-positive HNSCCs
had worse LRC (Figure 1B). Because PTEN and N-status are
independent predictors for increased risk for locoregional failure
(Table 4), we performed a stratified analysis that revealed that also
within the subset of Nþ patients, PTEN positivity identified
patients with significantly worse LRC (Po0.001) (Figure 1C).
In the current study population, the primary anatomical site of the
tumour had no significant effect on LRC (data not shown) and no
significant interactions were found between the anatomical site of
the tumour and IHC staining with respect to LRC, indicating that
the effect of PTEN on LRC did not depend on tumour site.
Increased PTEN expression induces increased
radioresistance in vitro
Our data based on IHC suggests that increased PTEN expression
might affect the radiosensitivity of tumour cells. To investigate
Table 3 Cross-table EGFR FISH and EGFR IHC
EGFR FISH
Normal Amplification Total
EGFR IHC
Low 101 (99) 1 (1) 102
High 3 (19) 13 (81) 16
Total 104 14 118
Abbreviations: EGFR¼epidermal growth factor receptor; FISH¼fluorescent in situ
hybridisation; IHC¼immunohistochemistry. Fischer exact test: Po0.001. Specificity,
97%; sensitivity, 93%.
Table 2 Cross-tables showing the correlations between the expression
levels of different proteins
(a)
pEGFR
Low High Total
EGFR
Low 78 (63) 45 (37) 123
High 6 (35) 11 (65) 17
Total 84 56 140
Pearson’s w
2-value is 4.9; P¼0.027
(b) pEGFR
Low High Total
pERK
Negative 78 (66) 40 (34) 118
Positive 6 (27) 16 (72) 22
Total 84 56 140
Pearson’s w
2-value is 11.6; P¼0.001
(c) PI3K p110
Low High Total
pERK
Negative 63 (53) 55 (47) 118
Positive 19 (86) 3 (14) 22
Total 82 58 140
Pearson’s w
2-value is 8.3; P¼0.004
(d) PI3K p110
Low High Total
Her2
Negative 79 (61) 50 (39) 129
Positive 3 (27) 8 (73) 11
Total 82 58 140
Pearson’s w
2-value is 4.8; P¼0.028
(e) PTEN
Low High Total
pERK
Negative 86 (71) 32 (29) 118
Positive 11 (50) 11 (50) 22
Total 97 43 140
Pearson’s w
2-value is 4.6; P¼0.033
(f) PTEN
Low High Total
pAKT
Low 81 (77) 24 (23) 105
High 16 (46) 19 (54) 35
Total 97 43 140
Pearson’s w
2-value is 12.2; Po0.001
Abbreviations: EGFR¼epidermal growth factor receptor; HER2¼human
epidermal growth factor receptor 2; pAKT¼phosphorylated protein kinase B;
pEGFR¼phospho-EGFR; pERK¼phosphorylated extracellular signal-regulated
kinase; PI3K¼phosphoinositide 3-kinase; PTEN¼phosphatase and tensin homo-
logue deleted on chromosome 10.
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overexpressed the PTEN protein in Hek293 cells (Figure 2B) and
tested the sensitivity to radiation in vitro by in vitro clonogenic
assays. The PTEN-overexpressing Hek293 cells clearly showed
increased radiation resistance compared with the empty vector
control (Figure 2A).
DISCUSSION
The role of EGFR in oncogenesis is widely accepted, as activation
of the receptor is known to result in important cancer hallmarks
such as proliferation and resistance to apoptosis (Hanahan and
Weinberg, 2000). Numerous studies reported on the prognostic
value of overexpression of EGFR in many tumour types including
HNSCC. The different studies on EGFR in HNSCC are unable to
reach consensus on the effect of EGFR overexpression on the
clinical outcome (Supplementary Table 2). Reasons for the
inconsistency in the IHC could be the different antibodies used,
no standard cutoff percentage for dichotomising the data and no
consensus on the localisation of staining in the cell. In HNSCC, the
percentage of EGFR-positive cases varies from 10 to 90%
(Supplementary Table 2). Compared with these studies, the
percentage of EGFR-positive cases in our study is low (12%).
The association between EGFR positivity and low-stage tumours is
unusual. We hypothesise that this could be related to the selection
of our patient series, that is, only patients who received primary
surgery and postoperative radiotherapy were included.
The total number of EGFR-positive cases with either complete or
incomplete circumferential immunostaining of the tumour cell
membranes was 19% (27 of 140 cases). However, FISH analysis
to determine EGFR gene copy number changes revealed that
only complete circumferential immunostaining of the tumour cell
membranes using the EGFR113 antibody was a very specific and
sensitive marker for amplification of the EGFR gene. As IHC
stainings are more routinely performed than FISH analysis in
many institutes, the antibody and the protocol that we used could
very well be used as a pseudomarker for amplification. The
frequency that we found is in good agreement with the previously
described amplification frequency of EGFR in HNSCC (Freier et al,
2003; Koynova et al, 2005; Temam et al, 2007).
Recently, both hrHPV positivity and p16 positivity in HNSCC
have been reported as very strong prognostic markers for clinical
outcome (Chung and Gillison, 2009). In addition, EGFR expression
has been inversely associated with the presence of HPV (Kong
et al, 2009). To determine whether HPV positivity is related with
LRC in our series and associated with EGFR expression, using a
semi-quantitative HPV16-/HPV18-specific PCR, as well as the
GP5þ/6þ and CPI/IIg consensus PCR as reported previously
(Wisman et al, 2006), only two cases were high-copy HPV16
positive (data not shown). Immunostaining for p16 revealed
expression in six cases (3 of 25 oropharyngeal and 3 of 79 oral
carcinomas). In the current literature, p16 positivity and hrHPV
positivity is mainly reported in carcinomas in the oropharyngeal
area (Machado et al, 2010). The relative low number of
HPV-positive and p16-positive cases in our series is most probably
because of the fact that our study contains only 25 oropharyngeal
carcinomas (18%).
In addition, we observed a significant association between
PTEN and pAKT. Phosphatase and tensin homologue deleted on
chromosome 10 was originally identified as an antagonist of the
AKT pathway, as expression resulted in decreased activation of
AKT (Sarbassov et al, 2005). We found that PTEN expression is
not only associated with higher pAKT levels but also with nuclear
localisation of pERK, both indicators of EGFR pathway activation.
These data suggested that the EGFR pathway is more activated in
PTEN-positive than in PTEN-negative HNSCC. The positive
correlation between PTEN and pAKT has recently been described
in ovary cancer (Wang et al, 2005; de Graeff et al, 2008), breast
cancer (Panigrahi et al, 2004) and malignant melanoma (Slipicevic
et al, 2005). The AKT was reported to become activated by PDK1
(on threonine 308) and by PDK2 (on serine 473), in case AKT is
bound to PIP3. Phosphatase and tensin homologue deleted on
chromosome 10 dephosphorylates PIP3 to PIP2, by which AKT
cannot bind to it anymore and will therefore not be activated by
these kinases (Sarbassov et al, 2005). An alternative pathway for
Table 4 Cox regression analysis on IHC and clinical factors, both
univariate and multivariate
Cox regression N (%)
Hazard ratio (HR) for LRR
(95% CI; P-value)
Univariate
EGFR
Low 123 (89) 1
High 17 (11) 0.5 (0.1–2.0; P¼0.32)
pEGFR
Low 84 (60) 1
High 56 (40) 1.2 (0.6–2.6; P¼0.58)
PI3K
Low 87 (62) 1
High 53 (38) 0.6 (0.3–1.4; P¼0.25)
PTEN
Low 97 (69) 1
High 43 (31) 2.4 (1.2–5.0; P¼0.019)*
pAKT
Low 105 (75) 1
High 35 (25) 2.2 (1.0–4.6; P¼0.043)*
pERK
Negative 118 (84) 1
Positive 22 (16) 1.2 (0.5–3.0; P¼0.65)
HER2
Low 129 (92) 1
High 11 (8) 1 (0.2–4.2; P¼0.99)
Lymph nodes
Negative 50 (36) 1
Positive 90 (64) 5.7 (2.0–16.3; P¼0.001)*
ENS
No 89 (64) 1
Yes 51 (36) 5 (2.4–10.6; Po0.001)*
Surgical margins
Free 43 (31) 1
Not free 97 (69) 1.4 (0.6–3.2; P¼0.37)
Multivariate
PTEN
Low 97 (69) 1
High 43 (31) 2.2 (1.1–4.6; P¼0.03)*
Lymph nodes
Negative (N0) 50 (36) 1
Positive (N+) 90 (64) 5.7 (1.2–27.4; P¼0.03)*
ENS
No 89 (64) 1
Yes 51 (36) 2.7 (1.2–6.5; P¼0.02)*
Abbreviations: CI¼confidence interval; EGFR¼epidermal growth factor receptor;
ENS¼extra nodal spread; HER2¼human epidermal growth factor receptor 2;
IHC¼immunohistochemistry; pAKT¼phosphorylated protein kinase B; pEGFR¼
phospho-EGFR; pERK¼phosphorylated extracellular signal-regulated kinase;
PI3K¼phosphoinositide 3-kinase; PTEN¼phosphatase and tensin homologue
deleted on chromosome 10. *Po0.05.
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sthe phosphorylation of AKT is the integrin pathway. It has been
reported that the integrin-linked kinase (ILK) is able to
phosphorylate AKT at ser473, independent of the PI3K pathway
(Persad et al, 2000). Tumours that are positive for PTEN seem to
have an alternative way of activating AKT and ERK, and the ILK
pathway might well be that way.
In our study, both positive PTEN and positive pAKT staining
showed a significantly increased risk for LRR. In addition, the
presence of extranodal spread and lymph node metastases revealed
a significantly increased risk. A multivariate analysis for LRR for
these four variables revealed that PTEN status, N-stage and
extranodal spread are all independent significant factors, indicat-
ing that the PTEN status could have an additive value in
determining the prognosis of advanced-stage HNSCC, next to the
already used clinical factors of N-stage and extranodal spread.
To support the results of our IHC staining, we performed a
clonogenic assay on Hek293 cells, transfected with an over-
expression plasmid for PTEN, and compared it with the same cell
line transfected with an empty vector. These in vitro data are in
line with our findings in the patient series, that is, higher
expression of PTEN leads to reduced radiosensitivity. To our
knowledge, we are the first to publish this effect of PTEN on
radiosensitivity in vitro.
The PTEN/MMAC1 was originally described as a tumour
suppressor in a large variety of malignant tumours (Li et al,
1997; Panigrahi et al, 2004; Guney et al, 2007). In numerous cancer
cell lines and primary tumours, mutations in the PTEN gene and
loss of heterozygosity or homozygous deletions have been found
(Cairns et al, 1997; Guldberg et al, 1997; Guney et al, 2007). As
described earlier, PTEN regulates AKT activity through dephos-
phorylation of PIP3 (Sarbassov et al, 2005). More recently, two
alternative functions for PTEN associated with its nuclear
localisation were described (Shen et al, 2007). First, PTEN has a
role in maintaining chromosomal stability by forming a complex
with the CENP-C protein that binds and stabilises centromeres.
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Figure 1 Kaplan–Meier analysis for locoregional control. (A) Comparing N0 with Nþ cases. (B) Comparing phosphatase and tensin homologue deleted
on chromosome 10 (PTEN)  with PTENþ cases. (C) Comparing N0 with Nþ/PTEN  and Nþ/PTENþ cases.
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Figure 2 (A) Clonogenic assay, comparing the radiosensitivity of
Hek293 cell line stabile transfected with an empty vector or with a
plasmid overexpressing phosphatase and tensin homologue deleted on
chromosome 10 (PTEN). (B) Western blot analysis for PTEN, RAD51 and
b-actin. Notice that overexpression of PTEN is associated with over-
expression of Rad51 in the stabile transfected PTEN cell line.
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the double strand break (DSB) repair protein Rad51, resulting
in upregulation of Rad51 (Shen et al, 2007; Yin and Shen,
2008). Interestingly, Rad51 expression was also upregulated in
our radiation-resistant, PTEN-overexpressing transfectants
(Figure 2B), which was in good agreement with the reported
study (Shen et al, 2007). The protein Rad51 has been studied
extensively and described to repair DSB through homologous
recombination (Raderschall et al, 2002; Shen et al, 2007;
Klein, 2008). The Rad51
 /  mice are not viable (Lim and Hasty,
1996) and DT40 Rad51 knockdown cells have been reported
to accumulate chromosomal breaks during the replication and
arrest in the G2/M phase of the cell cycle (Sonoda et al, 1998).
Furthermore, overexpression of the Rad51 protein has been
reported to increase the radioresistance of cell lines (Lundin
et al, 2003). The association between PTEN overexpression and
both worse LRC in patients as well as radioresistance in cell
lines (this study) might therefore be explained through the
overexpression of Rad51.
In conclusion, PTEN-positive HNSCC have a worse LRC when
treated with primary surgery and postoperative radiotherapy.
In these tumours, the AKT pathway is more frequently activated
than in PTEN-negative tumours. A PTEN-overexpressing HEK293
cell line is more radiation resistant than the empty vector-
transfected control cells, and in this overexpressing cell line
RAD51 is upregulated. We therefore propose that the mechanism
by which PTEN-positive HNSCC have a worse LRC is through
upregulation of RAD51, leading to better DSB repair.
Supplementary Information accompanies the paper on British
Journal of Cancer website (http://www.nature.com/bjc)
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